127 related articles for article (PubMed ID: 11317172)
1. No gender effect on binding characteristics of phenytoin to serum proteins in monotherapy for adult patients with epilepsy.
Kodama H; Kodama Y; Shinozawa S; Kanemaru R; Todaka K; Mitsuyama Y
Am J Ther; 2000 Sep; 7(5):285-9. PubMed ID: 11317172
[TBL] [Abstract][Full Text] [Related]
2. Effect of temperature on binding characteristics of phenytoin to serum proteins in monotherapy adult patients with epilepsy.
Kodama H; Kodama Y; Shinozawa S; Kanemaru R; Todaka K; Mitsuyama Y
Am J Ther; 2000 Jan; 7(1):11-5. PubMed ID: 11319568
[TBL] [Abstract][Full Text] [Related]
3. In vivo binding characteristics of phenytoin to serum proteins in monotherapy for adults with epilepsy.
Kodama H; Kodama Y; Shinozawa S; Kanemaru R; Todaka K; Mitsuyama Y
Am J Ther; 2000 Nov; 7(6):359-63. PubMed ID: 11304643
[TBL] [Abstract][Full Text] [Related]
4. In vivo binding characteristics of phenytoin to serum proteins in monotherapy pediatric patients with epilepsy.
Kodama H; Kodama Y; Shinozawa S; Kanemaru R; Itokazu N; Sugimoto T
Int J Clin Pharmacol Ther; 2000 Jan; 38(1):25-9. PubMed ID: 10667833
[TBL] [Abstract][Full Text] [Related]
5. Temperature effect on serum protein binding kinetics of phenytoin in monotherapy patients with epilepsy.
Kodama H; Kodama Y; Shinozawa S; Kanemaru R; Todaka K; Mitsuyama Y
Eur J Pharm Biopharm; 1999 May; 47(3):295-8. PubMed ID: 10382115
[TBL] [Abstract][Full Text] [Related]
6. Effect of temperature on serum protein binding characteristics of phenytoin in monotherapy paediatric patients with epilepsy.
Kodama H; Kodama Y; Itokazu N; Shinozawa S; Kanemaru R; Sugimoto T
J Clin Pharm Ther; 2001 Jun; 26(3):175-9. PubMed ID: 11422600
[TBL] [Abstract][Full Text] [Related]
7. Estimation of population pharmacokinetic parameters of free-phenytoin in adult epileptic patients.
Deleu D; Aarons L; Ahmed IA
Arch Med Res; 2005; 36(1):49-53. PubMed ID: 15777995
[TBL] [Abstract][Full Text] [Related]
8. Vigabatrin-induced decrease in serum phenytoin concentration does not involve a change in phenytoin bioavailability.
Gatti G; Bartoli A; Marchiselli R; Michelucci R; Tassinari CA; Pisani F; Zaccara G; Timmings P; Richens A; Perucca E
Br J Clin Pharmacol; 1993 Dec; 36(6):603-6. PubMed ID: 12959280
[TBL] [Abstract][Full Text] [Related]
9. Serum protein binding kinetics of phenytoin in monotherapy patients.
Kodama H; Kodama Y; Shinozawa S; Kanemaru R; Todaka K; Mitsuyama Y
J Clin Pharm Ther; 1998 Oct; 23(5):361-5. PubMed ID: 9875684
[TBL] [Abstract][Full Text] [Related]
10. Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients.
Sachdeo RC; Sachdeo SK; Levy RH; Streeter AJ; Bishop FE; Kunze KL; Mather GG; Roskos LK; Shen DD; Thummel KE; Trager WF; Curtin CR; Doose DR; Gisclon LG; Bialer M
Epilepsia; 2002 Jul; 43(7):691-6. PubMed ID: 12102670
[TBL] [Abstract][Full Text] [Related]
11. Phenytoin use in elderly nursing home residents.
Birnbaum AK; Hardie NA; Conway JM; Bowers SE; Lackner TE; Graves NM; Leppik IE
Am J Geriatr Pharmacother; 2003 Dec; 1(2):90-5. PubMed ID: 15555471
[TBL] [Abstract][Full Text] [Related]
12. Coadministration of phenytoin and felbamate: evidence of additional phenytoin dose-reduction requirements based on pharmacokinetics and tolerability with increasing doses of felbamate.
Sachdeo R; Wagner ML; Sachdeo S; Shumaker RC; Lyness WH; Rosenberg A; Ward D; Perhach JL
Epilepsia; 1999 Aug; 40(8):1122-8. PubMed ID: 10448826
[TBL] [Abstract][Full Text] [Related]
13. Intravenous phenytoin: a retrospective analysis of Bayesian forecasting versus conventional dosing in patients.
Tobler A; Mühlebach S
Int J Clin Pharm; 2013 Oct; 35(5):790-7. PubMed ID: 23812678
[TBL] [Abstract][Full Text] [Related]
14. Dose adjustment of phenytoin for comedication in Japanese patients with epilepsy.
Fukuoka N; Uno J; Tsukamoto T; Houchi H; Kimura M; Morita S
Ther Drug Monit; 2009 Feb; 31(1):57-62. PubMed ID: 19077928
[TBL] [Abstract][Full Text] [Related]
15. Binding parameters of phenytoin during monotherapy and polytherapy.
Pospísil J; Perlík F
Int J Clin Pharmacol Ther Toxicol; 1992 Jan; 30(1):24-8. PubMed ID: 1348053
[TBL] [Abstract][Full Text] [Related]
16. Phenytoin half-life and clearance during maintenance therapy in adults and elderly patients with epilepsy.
Ahn JE; Cloyd JC; Brundage RC; Marino SE; Conway JM; Ramsay RE; White JR; Musib LC; Rarick JO; Birnbaum AK; Leppik IE
Neurology; 2008 Jul; 71(1):38-43. PubMed ID: 18591503
[TBL] [Abstract][Full Text] [Related]
17. Differences between the measured and calculated free serum phenytoin concentrations in epileptic patients.
Hong JM; Choi YC; Kim WJ
Yonsei Med J; 2009 Aug; 50(4):517-20. PubMed ID: 19718399
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of phenytoin serum levels following a loading dose in the acute hospital setting.
Selioutski O; Grzesik K; Vasilyeva ON; Hilmarsson Á; Fessler AJ; Liu L; Gross RA
Seizure; 2017 Nov; 52():199-204. PubMed ID: 29073585
[TBL] [Abstract][Full Text] [Related]
19. Serum albumin-adjusted phenytoin levels: an approach for predicting drug efficacy in patients with epilepsy, suitable for developing countries.
Tandon M; Pandhi P; Garg SK; Prabhakar SK
Int J Clin Pharmacol Ther; 2004 Oct; 42(10):550-5. PubMed ID: 15516024
[TBL] [Abstract][Full Text] [Related]
20. Gender- or age-related binding characteristics of valproic acid to serum proteins in adult patients with epilepsy.
Kodama Y; Kodama H; Kuranari M; Tsutsumi K; Ono S; Yukawa E; Fujimura A
Eur J Pharm Biopharm; 2001 Jul; 52(1):57-63. PubMed ID: 11438424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
